CONGRESS ABSTRACT

Background : Mavacamten, a selective cardiac myosin inhibitor, improves left ventricular outflow tract (LVOT) obstruction and symptoms in obstructive hypertrophic cardiomyopathy (HCM). However, real-world data integrating cardiopulmonary exercise testing (CPET) and echocardiography remain limited. Methods : In this prospective multicenter study, 28 patients with symptomatic obstructive HCM underwent transthoracic…

Background: Hypertrophic cardiomyopathy (HCM) is a complex disease in which left ventricular outflow tract (LVOT) obstruction influences both functional capacity and clinical outcomes. However, the clinical relevance of varying obstruction severity remains debated. Objectives: To evaluate the relationship between LVOT gradient severity and both exercise performance and long-term prognosis…

Introduction Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous myocardial disease characterized by marked phenotypic variability, even among carriers of the same pathogenic mutation. Pregnancy in women with obstructive HCM represents a high-risk condition, particularly in the presence of severe left ventricular outflow tract (LVOT) obstruction and limited pharmacological options….

Background: Genetic testing in hypertrophic cardiomyopathy (HCM) shows variable genotype positivity, not consistently predicted by clinical features or severity. Identifying clinical predictors of genotype positivity could improve pre-test counseling and refine expectations, given the typical 30-50% yield of genetic testing in HCM, which varies across cohorts and settings. Methods:…

Metabolic syndrome (MetS) is a major predictor of adverse cardiac events associated with cardiac hypertrophy (CH). From a pathophysiological perspective, oxidative stress and redox status imbalance may play a pivotal role. In other pathological contexts, dysregulation of S-glutathionylation, a redox-dependent post-translational protein modification involving the conjugation of glutathione to…

Background: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) frequently present with exertional intolerance and features of heart failure with preserved ejection fraction (HFpEF). Although sodium–glucose cotransporter 2 inhibitors (SGLT2i) have shown clinical benefit in HFpEF, patients with hypertrophic cardiomyopathy have been excluded from major randomized trials, leaving a relevant unmet…